Soligenix Inc  

(Public, OTCBB:SNGX)   Watch this stock  
Find more results for OTC:SNGX
-0.001 (-0.12%)
May 6 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.76 - 0.85
52 week 0.44 - 2.95
Open 0.79
Vol / Avg. 66,800.00/58,321.00
Mkt cap 26.96M
P/E     -
Div/yield     -
EPS -0.32
Shares 31.37M
Beta 2.41
Inst. own 0%
May 12, 2016
Q1 2016 Soligenix Inc Earnings Release (Estimated) Add to calendar
Mar 24, 2016
Q4 2015 Soligenix Inc Earnings Release

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -69.25% -89.31%
Operating margin -75.61% -81.09%
EBITD margin - -78.27%
Return on average assets -120.17% -109.21%
Return on average equity - -
Employees 16 -
CDP Score - -


29 Emmons Dr Ste C10
PRINCETON, NJ 08540-5919
United States - Map
+1-609-5388200 (Phone)
+1-609-4526467 (Fax)

Website links


Soligenix, Inc. is a late-stage biopharmaceutical company. The Company develops product candidates in the areas of inflammation, oncology and biodefense. It operates in two segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment is developing a first-in-class photo-dynamic therapy (SGX301) utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, formulations of oral beclomethasone 17,21-dipropionate for the prevention or treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201), and its innate defense regulator (IDR) technology (SGX942) for the treatment of oral mucositis. The Vaccines/BioDefense segment includes development programs for RiVax, its ricin toxin vaccine candidate, VeloThrax, an anthrax vaccine candidate, OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate and SGX943, a melioidosis therapeutic candidate.

Officers and directors

Christopher J. Schaber Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 48
Joseph M. Warusz CPA Acting Chief Financial Officer, Vice President - Finance, Corporate Secretary
Age: 58
Oreola Donini Ph.D. Senior Vice President, Chief Scientific Officer
Age: 43
Richard C Straube M.D. Senior Vice President and Chief Medical Officer
Age: 63
Marco Maria Brughera Director
Age: 59
Keith L. Brownlie CPA Independent Director
Age: 62
Gregg A. Lapointe CPA Independent Director
Age: 56
Robert Joseph Rubin Independent Director
Age: 69
Jerome B. Zeldis M.D., Ph.D. Independent Director
Age: 65